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Hyperactivity of the orexin system within the paraventricular nucleus (PVN) has
been shown to contribute to increased sympathetic nerve activity (SNA) and blood
pressure (BP) in rodent animals. However, the underlying molecular mechanisms
remain unclear. Here, we test the hypothesis that orexin system activation stimulates
calcium/calmodulin-dependent kinase II (CaMKII) expression and activation, and
stimulation of CaMKII expressing PVN neurons increases SNA and BP. Real-time PCR
and/or western blot were carried out to test the effect of orexin-A administration on
CaMKII expression in the PVN of normal Sprague Dawley (SD) rats and orexin receptor 1
(OX1R) expressing PC12 cells. Immunostaining was performed to assess OX1R cellular
localization in the PVN of SD rats as well as orexin-A treatment on CaMKII activation in
cultured hypothalamic neurons. In vivo sympathetic nerve recordings were employed to
test the impact of optogenetic stimulation of CaMKII-expressing PVN neurons on the
renal SNA (RSNA) and BP. The results showed that intracerebroventricular injection of
orexin-A into the SD rat increases mRNA expression of CaMKII subunits in the PVN.
In addition, Orexin-A treatment increases CaMKII expression and its phosphorylation
in OX1R-expressing PC12 cells. Furthermore, Orexin-A treatment increases CaMKII
activation in cultured hypothalamic neurons from neonatal SD rats. Finally, optogenetic
excitation of PVN CaMKII-expressing neurons results in robust increases in RSNA and
BP in SD rats. Our results suggest that increased orexin system activity activates
CaMKII expression in cardiovascular relevant regions, and this may be relevant to the
downstream cardiovascular effects of CaMKII.
Keywords: CaMKII, orexin-A, paraventricular nucleus, sympathetic nerve activity, blood pressure

INTRODUCTION
Orexin-A and orexin-B are neuronal peptides processed from the same precursor, prepro-orexin,
which is produced by a small number of neurons located in the lateral hypothalamus (Meister
and Hakansson, 1998; Sakurai et al., 1998). Although originally recognized as regulators of feeding
behavior and wakefulness (Sakurai et al., 1998; Sakurai, 2002), orexins are now regarded as multifunctional peptides that coordinate numerous physiological, and subsequently pathophysiological
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involving cell cultures, brain tissues and whole animal studies to
investigate the role of OX1R activation on CaMKII expression
and activation, as well as the downstream effect of CaMKIIneuron specific activation on SNA and BP.

processes (Thannickal et al., 2000; Harris et al., 2005). The
actions of orexin neuropeptides are mediated by orexin receptor
1 (OX1R) and orexin receptor 2 (OX2R), two G-protein coupled
receptors (Sakurai et al., 1998; Scammell and Winrow, 2011).
The two receptors present specificity in their binding affinity
to the orexin neuropeptides, with OX1R having a much higher
affinity for orexin-A than for orexin-B, whereas the OX2R binds
both orexin peptides with a similar affinity (Sakurai et al., 1998).
Although orexin-A is only produced by a limited number of
neurons within the lateral hypothalamic area, orexin receptors
innervate a vast number of brain and spinal cord structures
(Antunes et al., 2001), resulting in far-reaching influences
of the sequestered orexin-producing neurons. Through their
axonal synapses with their receptor-expressing neurons, they
convey signals to postsynaptic neurons, effectively regulating
their activities.
Recent efforts have been put forth to elucidate the mechanistic
involvement of orexins in blood pressure (BP) and cardiovascular
regulation. Studies have shown that orexin system activity is
increased in the hypothalamic paraventricular nucleus (PVN),
and upregulated orexin system activity is implicated in several
forms of hypertension, including salt-sensitive and obesityrelated hypertension (Zhou et al., 2015, 2019b; Huber et al.,
2017; Fan et al., 2018). Furthermore, antagonism or genetic
knockdown of the orexin receptors results in attenuated
BP in spontaneously hypertensive rats and obesity-associated
hypertensive rats (Li et al., 2013).Despite the clear influence of
orexin-A on cardiovascular health and sympathetic nerve activity
(SNA), the detailed mechanisms mediating the effect of orexin
system activity on BP regulation remain elusive.
Ca2+ /calmodulin-dependent protein kinase II (CaMKII) is
a key protein kinase that is regulated by the Ca2+ /calmodulin
complex (Kool et al., 2019). This multi-faceted complex has
been shown to coordinate many signaling cascades which further
regulate numerous physiological functions including learning
and memory (Kool et al., 2019). However, more recently, it
was observed that inhibition of hypothalamic CaMKII reduces
elevated BP and sympathetic nerve discharges in hypertension (Li
et al., 2017). These findings suggest that overactivation of CaMKII
in cardiovascular relevant regions of the brain, such as the PVN,
contributes to hypertension development, and maintenance
(Zhuang et al., 2016; Li et al., 2017; Zhou et al., 2019b).
Furthermore, binding of orexin-A with OX1R can increase
intracellular calcium influx (Lund et al., 2000; Putula et al., 2014).
Interestingly, increased intracellular calcium concentrations also
activate CaMKII (Worrell and Frizzell, 1991). This observation,
coupled with the emerging role of orexin and CaMKII in the
development of hypertension, offers new mechanistic insight into
the pathological development of cardiovascular dysfunction.
To this end, we hypothesize that the binding of orexin-A
to OX1R will trigger an increase in CaMKII activation and
expression. Therefore, we propose that increased orexin system
activity will result in increases in both CaMKII expression and
its activity in pre-sympathetic PVN neurons, which may lead
to molecular underpinnings responsible, at least in part, for
increases in SNA and ultimately hypertension development.
In this study, we utilize multiple state-of-the-art techniques
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MATERIALS AND METHODS
Animals
Adult Sprague Dawley (SD) rats were purchased from
Charles River Laboratories Inc. and housed in the Michigan
Technological University (MTU) animal care facility. The
rats were maintained at room temperature (20–24◦ C) with a
humidity of 55 ± 10%. Additionally, animals were maintained on
a 12 h light/dark cycle, and were given ad libitum access to food
and water. The rats were used for intracerebroventricular (ICV)
injection, optogenetic manipulation, renal SNA (RSNA), and BP
recordings as detailed below. All experimental procedures were
approved by the Michigan Technological University Institutional
Animal Care and Use Committee.

ICV Injection of Orexin-A in SD Rats
To determine the effects of orexin-A ICV injection on PVN
CaMKII expression, adult male SD rats were divided into two
groups (n = 6 /group) and received ICV injection of either
orexin-A (2 nmol) or vehicle control (0.9% NaCl). The detailed
procedures for ICV microinjection can be referred to in our
previous publication (Huber et al., 2017). Briefly, adult male SD
rats (10–12-week-old) were anesthetized with isoflurane (3%),
and injected with either orexin-A (2 nmol dissolved in 0.9% NaCl,
4 µl) or saline (0.9% NaCl, 4 µl) into the lateral ventricle using an
injection minipump (Micro 4, WPI). The stereotaxic coordinates
for ICV injection were as follows: 0.8–0.9 mm behind the bregma;
1.4–1.8 mm away from the midline; and 3.2–3.8 mm below the
surface of the brain. After injection, the rats were returned to
a clean cage where they naturally woke up and moved freely
several minutes later. Three hours following injection, animals
were euthanized, their PVN tissues were harvested, and real-time
PCR was performed to measure mRNA of two CaMKII subunits,
CaMKIIa and CaMKIIb.

Optogenetic Stimulation of PVN
CaMKII-Expressing Neurons and the
Measurement RSNA and BP
Male adult SD rats were randomly divided into two groups
(n = 3 per group) and received AAV-CaMKII-ChR2 (channelrhodopsin-2)-eYFP or a control vector, AAV-CaMKII-GFP, via
bilateral microinjection into the PVN. Four weeks following
viral vector microinjection, when transgenes were fully expressed
in the PVN, optogenetic stimulation of CaMKII neurons
were performed at different intensities and frequencies. BP
and RSNA in response to stimulation were recorded at each
specific stimulation level. The rats were anesthetized with an
intraperitoneal injection containing a mixture of α-chloralose
(80 mg kg−1 ) and urethane (800 mg kg−1 ) and the level of
anesthesia was assessed by lack of the pedal withdrawal reflex.
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for 1 h and then incubated with 100 nM of orexin-A for 6 h. The
PVN tissues or cell cultures were subjected to RNA extraction
using the RNeasy Mini Kit (Qiagen, United States). RNA (200–
300 ng) was reverse transcribed to cDNA in 20 µl of PCR
reaction system using the iScriptTM cDNA synthesis kit (Bio-Rad,
United States). The cDNA samples were then used as templates
and real-time PCR was performed to measure mRNA levels of
CaMKIIa (Rn01258147_m1) and CaMKIIb (Rn00572627_m1)
using TaqMan primers and probers manufactured by Applied
Biosystems (Foster City, CA, United States). The data were
normalized to GAPDH (Rn01775763_g1) mRNA for analysis.

They were then instrumented with an arterial catheter inserted
into the aorta through a femoral artery. The catheter was
connected to a pressure transducer to measure arterial BP (ABP).
After tracheal cannulation, rats were paralyzed with gallamine
triethiodide (25 mg·kg−1 ·h−1 iv) and artificially ventilated
with oxygen-enriched room air. After paralysis, anesthesia was
monitored by the stability of ABP and heart rate (HR). The
supplements equal to 10% of the initial dose were given
when needed. End-tidal PCO2 was continuously monitored and
maintained within normal limits (35 to 40 mmHg) by adjusting
ventilation rate (80 to 100 breaths/min) and/or tidal volume
(2.0 to 3.0 ml).
For the optogenetic stimulation, an optical fiber (200 µm
core diameter, 1.25 mm outer diameter ceramic zirconia ferrule,
Precision Fiber Products) was lowered into the PVN (1.2 to
1.6 mm caudal to the bregma, 0.5 mm lateral to the midline,
and 7.0 to 7.2 mm ventral to the dura). Optogenetic stimulation
(473 nm laser) was conducted and examined at different
intensities (1.0, 5.0, and 20.0 mW at 40 Hz, 5 ms pulse width) and
frequencies (10, 20, and 40 Hz with 20 mW end output, 5 ms pulse
width). Each stimulation occurred in a train of 3 trials, each trial
consisted of 10s stimulation on and 30s stimulation off (allowing
the BP to recover to the baseline level after each 10s stimulation).
Renal SNA recording and BP measurement were performed
as previously described (Gui et al., 2012; Huber et al., 2017; Fan
et al., 2018). Briefly, with the use of a left flank incision, a left
renal sympathetic nerve bundle was isolated from surrounding
tissue and mounted on a stainless-steel wire electrode (outer
diameter: 0.127 mm, A-M Systems) and covered with a
silicone-based impression material (Coltene, Light Body) to
insulate the recording from body fluids. The recorded signal
was directed to an alternating current amplifier (P511, Grass
Technologies) equipped with half-amplitude filters (bandpass:
100–1,000 Hz) and a 60-Hz notch filter. The processed signal
was rectified, integrated (10-ms time constant), and digitized
at a frequency of 5,000 Hz using a 1401 Micro3 analog-todigital converter and Spike2 software (version 7.04, Cambridge
Electronic Design, Cambridge, United Kingdom). Background
noise was determined by a bolus injection of hexamethonium
(30 mg/kg iv), a ganglionic blocker, at the end of the experiment
and was subtracted from all integrated values of SNA. The ABP
were recorded and measured with the Spike2 software.

The Effect of Orexin-A Treatment on
CaMKII Activation Using Human OX1R
Expressing PC12 (PC12-OX1R) Cells by
Western Blotting Methods
PC12-OX1R cells were divided into five groups and received
treatment with either vehicle control or orexin-A (100 nM)
for differing times (10, 30, 60, and 180 Mins). Cells were
then collected and subjected to western blot analysis to test
protein levels of CaMKII and CaMKII phosphorylation. Protein
samples (25 µg) were separated with 10% SDS-polyacrylamide
gel electrophoresis, transferred to nitrocellulose membranes,
and probed with mouse anti-CaMKIIa (1:200 dilution), mouse
anti-CaMKIIb (1:200 dilution), rabbit anti-P-CaMKII (1:200
dilution), or mouse anti-β-actin (1:200 dilution) antibodies (used
as a protein loading control). Hybrid protein bands were detected
with ECLTM Western Blotting Detection Reagents (Bio-Lab).
Protein bands representing CaMKIIa, CaMKIIb, and P-CaMKII
were quantified and normalized with the β-actin band using the
NIH ImageJ program (Bethesda, MD, United States)1 .

OX1R and CaMKII Immunoreactivity in
the PVN and Cultured Hypothalamic
Neurons
Immunofluorescence in PVN Tissue
Male adult SD rats (n = 3) were deeply anesthetized with 5%
isoflurane. Next, cold phosphate buffer saline (PBS) followed by
4% paraformaldehyde (PFA) in 1×PBS was used to transcardially
perfuse the animals. Following perfusion, the brains were
removed and kept in 4% PFA overnight at 4◦ C. Brains were then
transferred and kept in 30% sucrose in 1×PBS at 4◦ C until they
sank to the bottom. Brains were cut in 25-µm coronal sections,
and the sections containing the PVN area were used to perform
co-immunostaining of OX1R with either neuronal nuclei (NeuN,
a marker for neurons), glial fibrillary acidic protein (GFAP,
a marker for astrocyte), or ionized calcium-binding adaptor
molecule 1 (Iba1, a marker for microglia) to investigate in which
type of cells OX1R is primarily distributed within the PVN.
The sections (25 µm) were first incubated with PBS containing
0.2% triton-X-100 and 2% horse serum for 1 h, and then were
divided into three groups. Next, they were incubated in a cocktail
containing goat anti-OX1R antibody (1:50 dilution)/rabbit
anti-NeuN (1:50 dilution) (Group 1), goat anti-OX1R (1:50

Measurement of CaMKII mRNA Levels
With Real-Time PCR in PVN Tissue and
PC12-OX1R Cells
Real-time PCR (RT-PCR) was performed to measure mRNA
levels of two subunits of CaMKII, CaMKIIa, and CaMKIIb, in the
PVN tissues and cell cultures. For the measurement of CaMKII
mRNA levels, PC12-OX1R and control PC12 cells were incubated
with orexin-A (100 nM) or vehicle control for differing times
(3, 6, and 24 h). Cells were then collected and subjected to
real-time PCR to test mRNA expression levels of CaMKIIa and
CaMKIIb. To assess the role of Ca2+ Influx on Orexin-A Effect,
PC12-OX1R cells were pretreated with EGTA-AM (10 mM), a
membrane-permeable form of the Ca2+ -chelating agent EGTA,
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dilution)/rabbit anti-Iba1 (1:1000 dilution) (Group 2), or rabbit
anti-OX1R (1:200 dilution) /mouse anti-GFAP (1:200 dilution)
(Group 3) in the PBS for 48–72 h. The brain sections were
washed with PBS three times, 10 min each. Afterward, the brain
sections were incubated with a mixture of secondary antibodies:
Alexa Fluor 488 donkey anti-goat IgG/ Alexa Fluor 594 donkey
anti-rabbit IgG (Group 1-2), or Alexa Fluor 488 donkey antirabbit IgG/ Alexa Fluor 594 goat anti-mouse IgG (Group 3). All
secondary antibodies were diluted in 1:1000 solution. The brain
sections were washed again with PBS three times, 10 min each.
Lastly, the sections were mounted in Vectorshield (Vector Labs,
Burlingame, CA, United States) and images were taken with a
Leica DMIL fluorescence microscope.

Tukey post-hoc pair-wise multiple comparisons were conducted
to assess differences between treatments/conditions. A value of
P < 0.05 was considered to be statistically significant.

RESULTS
Central Administration of Orexin-A
Increases mRNA Expression of CaMKII
Subunits in the PVN of SD Rats
Intracerebroventricular injection of orexin-A into the SD rats
resulted in significant increases in the mRNA expression of
CaMKIIa (1.5-fold) and CaMKIIb (1.3-fold) compared to control
saline injection rats (Figure 1).

Primary Neuronal Culture Preparation and Testing
Neuronal cells were isolated from the hypothalamus of 1-day-old
SD rats as described previously (Shan et al., 2008). Next, cells were
plated in poly-D-lysine precoated 12-well cell culture plates (105
cells/well) in Neurobasal -A medium (Thermo Fisher Scientific)
supplemented with 2% B27+ (Thermo Fisher Scientific) and 1%
antibiotic-penicillin/streptomycin (Invitrogen). The cell cultures
were incubated at 37◦ C in a 5% CO2 incubator for 10–14 days
before orexin-A treatment.
After 10–14 days, these neuronal cultures were treated with 1
µM orexin-A or vehicle control for 15 min and fixed with 4%
PFA. They were then subjected to immunofluorescent staining
against P-CaMKII antibodies followed by a secondary antibody
incubation. The P-CaMKII immunoreactivity was observed
under a fluorescent microscope and images were taken.

OX1R Is Primarily Distributed in Neurons
in the PVN of SD Rats
Our previous study demonstrates that OX1R is the primary
orexin receptor distributed in the PVN of SD rats (Fan et al.,
2018). Given the heterogeneity in cell types within the PVN
(neurons, astrocytes, microglia), we sought to assess in which
type of cells OX1R is primarily expressed. Co-immunostaining
of OX1R with an antibody, either anti- NeuN (a marker
for neurons), anti-GFAP (a marker for astrocyte), or antiIba1 (a marker for microglia), showed that OX1R is primarily
distributed in NeuN-positive cells in the PVN (Figure 2A).
There is no co-localization of OX1R with Iba1 (Figure 2B).
OX1R immunoreactivity is also observed in some GFAP-positive
cells (Figure 2C). These suggest that PVN OX1R are primarily
distributed in neurons and some astrocytes.

Reagents and Antibodies
The reagents and antibodies utilized in the current study
have been outlined in Table 1. Orexin-A, gentamicin, and
EGTA-AM were purchased from Sigma-Aldrich Co. (St. Louis,
MO, United States). Goat anti-OX1R antibody was purchased
from OriGene Technologies (Rockville, MD, United States);
rabbit anti-OX1R antibody was a product of Alomone Labs
(Jerusalem, Israel); rabbit anti-NeuN and rabbit anti-GFAP
antibodies were products of Cell Signaling Technology (Danvers,
MA, United States); rabbit anti-Iba1 antibody was purchased
from Wako; Primary antibodies mouse anti-CaMKIIa, mouse
anti-CaMKIIb, and mouse anti-P-CaMKII were products of
Santa Cruz Biotechnology (Dallas TX, United States). Secondary
antibodies including goat anti-rabbit IgG (H+L) Alexa Fluor
488 and donkey anti-mouse IgG (H+L) Alexa Fluor 594
were purchased from Thermo Fisher Scientific (Waltham, MA,
United States). Real-time PCR primers specific for CaMKIIa
and CaMKIIb were purchased from Thermo Fisher Scientific
(Waltham, MA, United States). AAV-CaMKII-ChR2-eYFP and
AAV-GFP were purchased from the University of North
Carolina vector center.

Orexin-A Treatment Stimulates CaMKII
Expression and Activation in PC12-OX1R
Cells
Using PC12-OX1R cells, a recombinant human OX1R-expressing
neuron-like PC12 cells, we investigated whether OX1R activation
can increase CaMKII expression as well as activate CaMKII.
The control PC12 cells are derived from the rat adrenal
pheochromocytoma and do not express any orexin receptors.
Orexin-A treatment resulted in a time-dependent increase in
both CaMKIIa and CaMKIIb mRNA expression, with the
maximum increase occurring 6 h following orexin-A treatment
(CaMKIIa: 2.7-fold; CaMKIIb: 3.6-fold; P < 0.05) (Figure 3A) in
PC12-OX1R cells. In contrast, orexin-A treatment in PC12 cells
for 6 h does not cause any alteration in CaMKIIa and CaMKIIb
expression (Figure 3B). The increases in CaMKIIa and CaMKII
induced by orexin-A were completely abolished by EGTA-AM
(10 mM), a membrane-permeable form of the Ca2+ -chelating
agent EGTA (Figure 3C).
Consistent with real-time PCR data, western blot results
showed that orexin-A treatment resulted in a time-dependent
increase in CaMKIIa and CaMKIIb protein levels, with the
maximum increase occurring 24 h following orexin-A treatment
in CaMKIIa (2.6-fold) and 6 h after orexin-A treatment in
CaMKIIb (1.6-fold) (Figure 4A). Furthermore, treatment of

R

R

Statistical Analysis
All data are presented as the mean ± SEM. Depending on
the experiment, statistical analysis was conducted by either
independent samples t-test or one-way analysis of variance. If
statistical significance was observed in the ANOVA analysis,
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TABLE 1 | The information of the antibodies used in the study.
Antibodies

Company

Catalog number

Source

Dilutions for WB

Dilution for IF

OX1R

Acris

Ap31067pu-n

Goat

/

1:50

OX1R

Alomone labs

AOR-001

Rabbit

/

1:100

NeuN

Cell Signaling

mAb#24307

Rabbit

/

1:50

Iba1

Wako

019-19741

Rabbit

/

1:500

GFAP

Invitrogen

mAb#3670

Mouse

/

1:300

Anti-pCaMKII

Santa cruz

sc-32289

Mouse

1:1000

1:200

CaMKIIa

Santa cruz

sc-13141

Mouse

1:1000

/

CaMKIIb

Santa cruz

sc-376828

Mouse

1:1000

/

β-actin

Santa cruz

sc-47778

Mouse

1:1000

/

Primary antibodies

Secondary antibodies
Anti-goat 488

Invitrogen

A32814

Donkey

/

1:1000

Anti-rabbit 594

Invitrogen

A-21207

Donkey

/

1:1000

Anti-rabbit 488

Invitrogen

A-21206

Donkey

/

1:1000

Anti-mouse 594

Invitrogen

A-11005

Goat

/

1:1000

Anti-mouse IgG (HRP)

Invitrogen

PA1-28568

Rabbit

1 :2000

/

WB, western blot; IF, immunofluorescence.

induced CaMKII activation is mediated by OX1R activation. The
result shows that orexin-A treatment for 15 min significantly
increases P-CaMKII in hypothalamic neurons (Figure 5A).
Co-immunostaining of P-CaMKII and OX1R demonstrated
that CaMKII phosphorylation only occurs in OX1R expressing
neurons (Figure 5B).

Optogenetic Stimulation of PVN
CaMKII-Expressing Neurons Causes
Intensity-and Frequency-Dependent
Increase in RSNA and Blood Pressure

FIGURE 1 | ICV injection of orexin-A increases mRNA expression of CaMKIIa
and CamKIIb in the PVN of SD rats. Adult male SD rats received ICV injection
of either orexin-A or vehicle control. The rats were euthanized 3 h following
microinjection, and PVN tissue was harvested and subjected to real-time PCR
to measure mRNA expression of CaMKIIa (A) and CaMKIIb (B). The data
were normalized to GAPDH mRNA and the average mRNA levels in control
rats were assigned an arbitrary unit of 1 (n = 5/group). P = 0.006 for the
CaMKIIa mRNA (A) increase and P = 0.022 for the CaMKIIb mRNA (B)
increase. * P < 0.05.

To test the effect of PVN CaMKII expressing neurons on BP
and sympathetic outflow, we injected viral vector AAV-CaMKIIChR2-eYFP or control vector AAV-GFP viral vector into the PVN
of adult SD rats. ChR2 (channelrhodopsin-2) is a direct lightgated cation-selective membrane channel driven by the CaMKII
promoter and therefore is exclusively expressed in CaMKIIexpressing neurons (Nagel et al., 2003). Optogenetic stimulation
of the PVN neurons showed dramatic increases in RSNA
and BP in an intensity-dependent manner in AAV-CaMKIIChR2 injection rats. The maximum increase in RSNA (ChR2:
142.0 ± 31.7% vs. GFP: 3.1 ± 3.2%; P < 0.05) and mean arterial
pressure (MAP) (ChR2: 34 ± 4.5 vs. GFP: 0.6 ± 0.4, mmHg;
P < 0.05) occurred at the intensity of 20 mW, while no changes
were observed in control viral vector, AAV-GFP injected rats.
We further performed optogenetic stimulation of PVN neurons
using different frequencies including 10, 20, and 40 Hz with 20
mW end output, respectively. It showed a frequency-dependent
increase in RSNA and BP in AAV-CaMKII-ChR2 injection rats
with the maximum increases in RSNA (ChR2: 141 ± 39.2% vs.
GFP: 1.4 ± 1.3%, P < 0.05) and MAP (ChR2: 29.2 ± 6.1 vs. GFP:
1.4 ± 1.3 mmHg, P < 0.05) occurring at a frequency of 40 Hz.
Again, no changes were observed in control viral vector injection
rats (Figures 6A,B). This result demonstrated that excitation

PC12-OX1R cells with orexin-A (100nM) resulted in a timedependent increase in P-CaMKII, the activated form of the
enzyme. The increase in P-CaMKII began approximately 10 min
following orexin-A treatment, and reached a peak 30 min
following treatment. 1 h following orexin-A incubation, basal
levels of P-CaMKII were once again observed (Figure 4B).

Orexin-A Treatment Increases P-CaMKII
in Hypothalamic Neurons
Previous studies demonstrate that orexin-A can increase
intracellular free [Ca2+ ] through binding with OX1R. Increased
cytosolic [Ca2+ ] is known to be able to induce CaMKII
autophosphorylation, therefore activating its kinase activity. In
this experiment, we investigated whether orexin-A treatment
can activate CaMKII in hypothalamic neurons (i.e., increasing
P-CaMKII). If so, we wished to observe whether orexin-A

Frontiers in Physiology | www.frontiersin.org
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FIGURE 2 | PVN OX1R is primarily expressed in neurons in the SD rats. Representative images showing immunoreactivity of OX1R (green), neuronal nuclei NeuN
[red (A)], microglial marker Iba1 [red (B)], astrocyte marker GFAP [red (C)], and merged images in the PVN of SD rat. The area labeled in the dashed rectangle in the
upper panel was magnified and showed in the lower panel. The brain coronal sections were taken from 1.8 mm caudal from the bregma. 3V, the third ventricle.

of PVN CaMKII expressing neurons increase SNA and MAP.
Additionally, immunostaining of OX1R showed that OX1R is
co-localized with GFP which was only expressed in CaMKIIexpressing neurons. In particular, this co-localization was

Frontiers in Physiology | www.frontiersin.org

observed within the ventrolateral parvocellular (vlp) subdivision
of the PVN, a brain area rich in pre-sympathetic neurons
(Figure 6C; Stocker et al., 2004) suggesting that PVN OX1R is
expressed in the CaMKII-expressing neurons.
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FIGURE 3 | Orexin-A treatment increases mRNA expression of CaMKII subunits in PC12-OX1R cells. (A) Orexin-A (100 nM) stimulation induced a time-dependent
increase in mRNA expression of CaMKIIa (A1) and CaMKIIb (A2) subunits in PC12-OX1R cells. (B) Orexin-A (100 nM) treatment for 6 h induced increases in mRNA
expression of CaMKIIa (B1) and CaMKIIb (B2) subunits in PC12-OX1R, but not in PC12 cells. (C) The effect of orexin-A on CaMKII expression is blocked by
EGTA-AM. The data were normalized to GAPDH mRNA. Average control mRNA level was assigned as arbitrary unit 1 (n = 6 per group, *P < 0.05, ** P < 0.01,
*** P < 0.001).

observed in PC12 cells; (4) Orexin-A treatment in hypothalamic
neurons results in an increase in P-CaMKII, the activated form
of the enzyme; and (5) Optogenetic stimulation of PVN CaMKIIexpressing neurons results in increased RSNA and BP. Our results
suggest that activation of orexin system activity in the PVN
stimulates activation of the CaMKII pathway. This activation
may subsequently facilitate, to a certain degree, the pressor effect
observed by optogenetic stimulation of PVN CaMKII expressing
neurons, although this effect has not yet been established.
Orexin system dysfunction, specifically hyperactivity, has
been implicated in numerous experimental hypertensive animal

DISCUSSION
This study is the first to investigate the contribution of the
orexin system on the regulation of CaMKII, a key protein kinase
involved in multiple functions including cardiovascular function
and BP regulation (Mohler and Hund, 2011; Prasad et al., 2015).
We report five major findings: (1) Orexin-A ICV injections elicit
increased CaMKII mRNA expression in the PVN of SD rats; (2)
OX1R is primarily expressed in neurons and astrocytes within
the PVN; (3) Orexin-A treatment in PC12-OX1R cells results in
increased CaMKII expression and activation, but this was not

Frontiers in Physiology | www.frontiersin.org
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FIGURE 4 | Orexin-A treatment increases CaMKII subunits’ protein expression as well as CaMKII activation in PC12-OX1R cells. PC12-OX1R cells were incubated
with 100 nM orexin-A for the indicated periods. Proteins were separated and probed with CaMKIIa, CaMKIIb, P-CamKII, and β-actin antibodies. (A) Orexin-A
treatment increases CaMKII protein expression in a time-dependent manner. (A1) Representative western blots showing CaMKIIa, CaMKIIb, and β-actin in orexin-A
treated and control cells. Quantification of CaMKIIa (A2) and CaMKIIb (A3) that has been normalized against β-actin and compared with control, normalized to unity
(n = 6, *P < 0.05). (B) Orexin-A treatment results in a time-dependent increase in P-CaMKII level. (B1) representative western blots showing P-CaMKII and β-actin.
(B2) Quantification of P-CaMKII that has been normalized against β-actin and compared with control, normalized to unity (n = 6, *P < 0.05, **P < 0.01).

models including the Obese Zucker rats (Zhou et al., 2015,
2019b), spontaneously hypertensive rats (Li and Nattie, 2014;
Lee et al., 2015), and Dahl salt-sensitive rats (Huber et al., 2017).
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Furthermore, blockage of orexin receptors in the PVN has been
observed to attenuate hypertension development (Carrive, 2013;
Zhou et al., 2019a). However, the detailed mechanism mediating
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FIGURE 5 | Orexin-A treatment increases CaMKII activation in OX1R-expressing hypothalamic neurons. Hypothalamic neuronal cultures isolated from neonatal SD
rats were treated with 1 µM of orexin-A or vehicle control for 15 min, then cells were subjected to immunostaining using primary antibody anti-phospho-CaMKII
(P-CaMKII) or OX1R followed by incubation with fluorescent dye-labeled secondary antibody. (A) Orexin-A treatment increases P-CaMKII in hypothalamic neurons.
The area labeled in a solid rectangle in the left panel was higher magnified in the right panel. (B) Representative images show the immunostaining of P-CaMKII
(green), OX1R (red), and merged image in cultured PVN neurons under orexin-A treatment.

the effect of increased orexin system activity on hypertension
development is not clear.
Previous studies show that binding of orexin-A with its
receptors can cause calcium ion influx into the cytosol, increasing
intracellular calcium concentrations (Holmqvist et al., 2002;
Kohlmeier et al., 2008; Xia et al., 2009). However, the downstream
signaling cascade components triggered by increased intracellular
calcium is not clear. Calcium is a very important second
messenger and can bind to calcium calmodulin protein, leading
to CaMKII autophosphorylation, therefore activating its kinase
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activity (Wei et al., 2017). Interestingly, Li et al. (2017) observed
that CaMKII hyperactivity within the PVN modulates the activity
of the N-methyl-D-aspartate receptor, resulting in increased
sympathetic outflow. However, the cause of this increased
CaMKII activity has not been established. Given the similarly
elevated activity of the orexin system and CaMKII, as well as
the similar resultant increases in sympathetic activity and BP in
hypertensive animal models (Li et al., 2017; Zhou et al., 2019a),
we hypothesized that orexin signaling may lie upstream from
CaMKII activation.
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FIGURE 6 | Continued
the changes in RSNA and ABP in response to optogenetic stimulation of PVN
at different intensities (top)- and frequencies (low). *P < 0.05,
R
AAV-CaMKII-ChR2-eYFP vs AAV-CaMKII-GFP. Avg, average; , integrated.
(C) Immunostaining shows that PVN OX1R (red) and CaMKII (represented by
report gene GFP) are co-localized in the PVN neurons, in particular, in the
ventrolateral parvocellular (vlp) subdivision, a subdivision in the PVN rich in
pre-sympathetic neurons (Stocker et al., 2004). 3V, the third ventricle. Low
panel right is a magnified image of dashed line labeled area of the merged
image (low panel, left).

The present study shows that ICV administration of orexinA into SD rats triggers modest yet significant increase in mRNA
expression of CaMKII subunits, CaMKIIa and CaMKIIb, in the
PVN (Figure 1), indicating a causative relationship between
orexin-A release and CaMKII expression. This observation
coupled with the evidence that ICV injection of orexin-A
increases BP and sympathetic outflow in conscious SD rats
(Samson et al., 1999; Shirasaka et al., 1999) suggests that
hyperactivity of brain orexin system may, through stimulation
of PVN CaMKII expression, result in the previously observed
increases in SNA and BP. However, we are careful to note that this
hypothesis requires further testing. The reasons for the observed
moderate instead of high increase in CaMKII in response to
ICV orexin infusion have several possible explanations: First,
CaMKII and OX1R are expressed in the same cells in the PVN.
Upon binding of orexin-A and OX1R, the OX1R-expressing cells
undergo excitation which in turn elicits CaMKII expression.
This process only occurs in OX1R-positive cells. PVN OX1R
is primarily distributed in neurons as well as some astrocytes,
as opposed to microglial cells (Figure 2). Therefore, testing
CaMKII levels using whole PVN tissue samples, which also
contain many OX1R-negative cells, will dilute the actual CaMKII
increase which is reflected in our observations. Second, it is quite
possible that central ICV administration of orexin-A activates
OX1R distributed in other brain areas which through axonal
projections synapse with CaMKII-expressing neurons in the
PVN, impacting the observed expression levels. Third, in order to
minimize animal use, we tested CaMKII levels 3 h after OrexinA microinjection. However, it is worth noting that maximum
CaMKII increases may occur before or after 3 h post orexinA administration.
The stimulation effect of orexin-A on CaMKII expression
shown in ICV injection is strengthened by a time-dependent
increase in CaMKIIa and CaMKIIb mRNA and protein
expression in PC12-OX1R cells, but not in PC12 cells which lack
OX1R expression (Figures 3A,B), following orexin-A incubation.
This suggests selective stimulation of CaMKII expression,
specifically through downstream signaling associated with OX1R
and orexin-A binding. Interestingly, the increase in CaMKIIa and
CaMKIIb in PC12-OX1R was blocked by pre-incubation of the
cells with EGTA-AM (Figure 3C) which chelate calcium ions
(divalent cation), suggesting that increased intracellular calcium
ions due to OX1R activation mediate the increase in CaMKIIa
and CaMKIIb expression. This aligns with previous literature
observing the direct impact of orexin signaling on increased
calcium influx into the intracellular area and outlines CaMKII

FIGURE 6 | Optogenetic stimulation of CaMKII-expressing neurons in the
PVN increases renal sympathetic nerve activity (RSNA) and arterial blood
pressure (ABP). (A) Representative traces of RSNA and ABP during 10 sec
optogenetic stimulation in the PVN at the intensity of 1, 5, and 20 mW (5 ms
pulse duration) in AAV-CaMKII-ChR2-eYFP (left) and control vector AAV-GFP
(right) injected rats (Top panels); and representative traces of RSNA and ABP
during 10 sec optogenetic stimulation in the PVN at the frequency of 10, 20,
and 40 Hz (5-ms pulse duration and 20 mW) in AAV-CaMKII-ChR2-eYFP
(left) and AAV-GFP (right) injected rats (Low panel). (B) Population data showing
(Continued)
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as a downstream target of this cation influx (Holmqvist et al.,
2002). In addition to increased expression, western blot analysis
following orexin-A treatment revealed increased phosphorylated
CaMKII (P-CaMKII) expression, an active form of CaMKII
enzyme, in PC12-OX1R cells (Figure 4). The combination of
these results suggests that OX1R activation can increase CaMKII
expression and CaMKII activation.
While PC12 cells offer some mechanistic insight, their
physiological relevance may be questioned given that they
are not brain neurons. However, we observed similar results
in hypothalamic neuronal cells. P-CaMKII was significantly
elevated in response to orexin-A incubation (Figure 5), and
the P-CAMKII was exclusively shown in the OX1R-expressing
neurons, strengthening the role of orexin-A-OX1R binding in
CaMKII activation.
Lastly, our study shows that optogenetic stimulation of
CaMKII neurons resulted in drastic increases in RSNA and BP
(Figures 6A,B), replicating previous findings (Li et al., 2017).
While this does not specifically indicate a direct role for orexin
stimulation as a mediator of this process, it does show that PVN
activation of CaMKII leads to a sympathetic pressor response.
Since ICV injection of orexin-A into SD rats can increase their
BP and RSNA (Samson et al., 1999; Shirasaka et al., 1999),
upregulate PVN CaMKII expression (Figure 1), and excitation of
PVN CaMKII-expressing neurons can increase their sympathetic
outflow and BP (Figure 6), we speculate that increased orexin
signaling may, through CaMKII activation, result in increased
sympathetic outflow and BP, complimenting prior findings (Li
et al., 2017). However, further studies regarding this mechanism
are necessary to assess whether increased BP and SNA are
blocked in response to central orexin-A administration following
simultaneous Orexin-A microinjection and CaMKII inhibition.
Li et al. (2017) showed that inhibition of CaMKII activity within
the PVN using autocamtide-2-related inhibitory peptide resulted
in a significant reduction of both ABP and sympathetic outflow.
However, the effect of CaMKII inhibition on Orexin-A mediated
sympathetic and pressor responses remains yet to be elucidated,
although this outlines an exciting new avenue for future research.
Until tested, the relationship between the observed influence of
Orexin-A on CaMKII expression and its potential subsequent
impact on cardiovascular control remains speculative.
We acknowledge that the current study has some limitations.
First, as mentioned earlier, to confirm that the increased SNA
and pressor response induced by upregulated orexin signaling
is mediated by CaMKII activation, a CaMKII inhibitor needs
to be administered to test whether the increase in BP and
RSNA induced by ICV orexin-A microinjection can be abolished
or attenuated. Second, although orexin-A treatment results in
CaMKII activation in OX1R-expressing neurons in hypothalamic
primary neuronal cultures (Figure 5), CaMKII may also be
expressed in non-OX1R-expressing cells in the PVN. This is
particularly relevant due to the evidence showing that GFP
expression driven by the CaMKII promoter is not limited
to OX1R immunoreactive cells (Figure 6C). Therefore, the
pressor response observed following CaMKII excitation may be
a combined effect of multiple cells including OX1R-expressing
and OX1R-negative neurons. Third, increased orexin signaling
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FIGURE 7 | A proposed mechanism that OX1R activation on sympathetic
nerve activity and blood pressure regulation. Binding of orexin-A with OX1R
results in OX1R activation, which in turn triggers the influx of Ca2+ resulting in
intracellular Ca2+ increase. Ca2+ , in turn, activates CaMKII enzyme activity as
well as CaMKII expression, which eventually results in SNA increase and
blood pressure elevation.

may trigger other mechanisms such as neuronal hormone
secretion, in turn regulating BP further. This may be in part
due to the expansive PVN OX1R expression in not only presynaptic neuronal areas, but also areas involved in neurosecretory
processes as suggested by the prominent distribution of OX1R in
the magnocellular region of the PVN (Figure 6C).With regard
to the third possibility, recent studies from our group suggest
that activation of PVN OX1R can also increase PVN vasopressin
expression (Huber et al., 2017; Bigalke et al., 2021). The current
research study does not allow us to elucidate the vast number of
possible molecular mediators at play, although these limitations
offer future directions for exploration.
Calmodulin-dependent kinase II has been shown in recent
years to have an impact on the development of hypertension
(Zhuang et al., 2016; Li et al., 2017). Our results offer insight
into the upstream activity of the orexin system as a potential
mediator of the deleterious impact of CaMKII in the development
of hypertension, through excessive CaMKII activation. In
conjunction with the results of Li and colleagues (Li et al.,
2017), our proposed mechanism utilizes a feed-forward circuit,
whereby orexin overactivity results in calcium influx, which
activates CaMKII, resulting in modulation of pre-sympathetic
neuronal firing patterns (Figure 7). Furthermore, these results
strengthen the hypothesized role of the orexin system in BP
and cardiovascular regulation. Our study suggests that increased
orexin system activity may lead to an increase in CaMKII
expression and excitation of CaMKII positive PVN neurons.
Whether this over-abundance of orexin mediated CaMKII
activity results in increased SNA and BP remains unknown, and
is a target for future studies. This pathway offers a pertinent target
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for future research and warrants further investigation utilizing
hypertensive animal models.
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